Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832285 | 0.85 | TTR (0.42) | TACR1SCN9ANPC1RAB9AKDM4E | |
| SCHEMBL6832286 | 0.84 | AAK1 (0.45) | TACR1CTSSCTSKACEKLK5 | |
| SCHEMBL27856341 | 0.81 | GSTP1 (0.44) | TACR1CTSSCTSKACEKLK5 | |
| SCHEMBL3786067 | 0.81 | GSTP1 (0.44) | TACR1CTSSCTSKACEKLK5 | |
| SCHEMBL10249595 | 0.79 | TACR1 (0.45) | TACR1CTSSCTSKACEKLK5 | |
| SCHEMBL6832289 | 0.76 | ACE (0.41) | TACR1CTSSCTSKACEKLK5 | |
| SCHEMBL30759357 | 0.73 | KLK5 (0.55) | CTSSCTSKACEKLK5CTSL | |
| SCHEMBL12028561 | 0.73 | KLK5 (0.55) | CTSSCTSKACEKLK5CTSL | |
| SCHEMBL3770997 | 0.72 | ACE (0.45) | CTSSCTSKACESCN9APPARA | |
| SCHEMBL17468602 | 0.72 | CTSS (0.51) | CTSSCTSKACEKLK5CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | TACR1 3020/4885CTSS 1217/4885CTSK 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.